TY - JOUR
T1 - Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma
AU - Lim, Seah H.
AU - Wang, Zhiqing
AU - Chiriva-Internati, Maurizio
AU - Xue, Yuying
PY - 2001/3/1
Y1 - 2001/3/1
N2 - Various studies have demonstrated the aberrant expression of normal testicular proteins in neoplastic cells. These proteins collectively form the new class of tumor antigens called cancer-testis (CT) antigens. Their selective normal tissue expression makes them ideal antigens for immune targeting of the malignant disease. In this study, the expression of a spermatozoa protein, Sp17, in multiple myeloma was investigated. It was found that Sp17 is detectable in tumor cells from 12 of 47 (26%) myeloma patients. Reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis detected Sp17 transcripts and proteins, respectively. Northern blot analysis and RT-PCR demonstrated that Sp17 transcripts were detected only in normal testis, supporting its tissue specificity. Since a high proportion of normal individuals develop antibodies against Sp17 following vasectomy, Sp17 is likely to be a highly immunogenic protein in vivo. Sp17 is therefore a novel member of the CT antigen family and should be an ideal target for immunotherapy of multiple myeloma.
AB - Various studies have demonstrated the aberrant expression of normal testicular proteins in neoplastic cells. These proteins collectively form the new class of tumor antigens called cancer-testis (CT) antigens. Their selective normal tissue expression makes them ideal antigens for immune targeting of the malignant disease. In this study, the expression of a spermatozoa protein, Sp17, in multiple myeloma was investigated. It was found that Sp17 is detectable in tumor cells from 12 of 47 (26%) myeloma patients. Reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis detected Sp17 transcripts and proteins, respectively. Northern blot analysis and RT-PCR demonstrated that Sp17 transcripts were detected only in normal testis, supporting its tissue specificity. Since a high proportion of normal individuals develop antibodies against Sp17 following vasectomy, Sp17 is likely to be a highly immunogenic protein in vivo. Sp17 is therefore a novel member of the CT antigen family and should be an ideal target for immunotherapy of multiple myeloma.
UR - http://www.scopus.com/inward/record.url?scp=0035282736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035282736&partnerID=8YFLogxK
U2 - 10.1182/blood.V97.5.1508
DO - 10.1182/blood.V97.5.1508
M3 - Article
C2 - 11222401
AN - SCOPUS:0035282736
SN - 0006-4971
VL - 97
SP - 1508
EP - 1510
JO - Blood
JF - Blood
IS - 5
ER -